ALLMedicine™ Cutaneous Melanoma Center
Research & Reviews 1,671 results
https://doi.org/10.1038/s41388-021-01977-1 10.1038/nature12477 10.1038/nature22071 10.1016/j.ccell.2018.06.005 10.1056/NEJMoa1502583 10.1016/j.cell.2015.05.044 10.1038/ng1054 10.1007/s10585-018-9893-y 10.1038/s41467-021-21576-8 10.1101/gad.329771.119 10.1080/15592294.2014.1003746 10.1142/S2591722620400104 10.1038/nature17161 10.1038/s41594-018-0143-4 10.3390/cancers13061408 10.1038/s41580-020-0243-y 10.1016/j.tcb.2019.12.004 10.1080/15476286.2015.1020271 10.1016/j.molcel.2014.08.019 10.1016/j.cell.2015.02.014 10.1038/ncomms14741 10.1016/j.celrep.2014.12.019 10.1172/JCI62980 10.1016/j.molcel.2017.10.034 10.1186/s13059-014-0409-z 10.1261/rna.035667.112 10.1038/nature11928 10.1016/j.molcel.2015.03.027 10.1371/journal.pone.0030733 10.1371/journal.pgen.1003777 10.1186/s13059-015-0690-5 10.1186/s13059-015-0801-3 10.1016/j.celrep.2014.10.062 10.1038/nn.3975 10.1038/nature11993 10.1016/0092-8674(93)90279-Y 10.1016/j.cell.2011.07.014 10.1158/2159-8290.CD-13-0202 10.1038/cdd.2016.133 10.1093/nar/gkw027 10.1038/ncomms12429 10.1080/15476286.2017.1279788 10.1038/cdd.2017.86 10.1016/j.ymthe.2017.05.022 10.1038/nsmb.2959 10.1016/j.molcel.2013.08.017 10.1038/nplants.2017.53 10.1261/rna.048272.114 10.1016/j.molcel.2017.02.021 10.1038/cr.2017.31 10.1038/s41388-018-0230-3 10.1038/s41388-017-0019-9 10.1186/s13059-019-1685-4 10.1093/jnci/djx166 10.1186/s12943-019-1010-6 10.1038/s41467-018-06862-2 10.1016/j.molcel.2017.02.017 10.1093/nar/gkaa704 10.1038/emboj.2011.359 10.1371/journal.pgen.1007114 10.1016/j.ccell.2019.12.007 10.1038/s41467-020-18355-2 10.1016/j.isci.2020.101345 10.1126/science.aam8526 10.18632/oncotarget.9421 10.1016/j.bbrc.2012.11.086 10.3390/jcm4091668 10.2147/OTT.S131597 10.1007/s00432-016-2256-7 10.1186/s12935-019-0959-y 10.1016/j.cell.2012.10.002 10.1016/j.cell.2018.05.022 10.1186/s12943-020-01253-y 10.1159/000489208 10.2147/OTT.S207938 10.1097/CMR.0000000000000524 10.1016/j.lfs.2020.117323 10.1016/j.bbrc.2018.05.114 10.1016/j.biopha.2018.08.152 10.1186/s12957-020-01832-9 10.1038/s41419-020-2444-x 10.1186/s12943-020-01191-9 10.1177/0960327120950014 10.1007/s11010-020-03875-8 10.1007/s12013-019-00895-0 10.1038/s41419-020-02799-x 10.1016/j.canlet.2019.05.036 10.1101/gad.270421.115 10.1186/s13059-021-02263-9 10.1038/cr.2015.82 10.1371/journal.pone.0148407 10.1038/jid.2010.222 10.3390/ijms21061930
Oncogene Mecozzi N, Vera O et. al.
Aug 1st, 2021 - Non-coding RNAs are emerging as critical molecules in the genesis, progression, and therapy resistance of cutaneous melanoma. This includes circular RNAs (circRNAs), a class of non-coding RNAs with distinct characteristics that forms through non-c...
https://doi.org/10.1111/dth.15067
Dermatologic Therapy; Li J, Wang J et. al.
Jul 25th, 2021 - The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. This retrospective study analyzed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or ...
https://doi.org/10.1097/CMR.0000000000000763
Melanoma Research; Torricelli C, Carron J et. al.
Jul 21st, 2021 - Cutaneous melanoma is the most aggressive skin cancer with high mortality. Proinflammatory cytokines can modulate the proliferation and survival of cutaneous melanoma cells. Higher levels of interleukin-1β (IL1B) were associated with tumor cell pr...
https://doi.org/10.1007/s00431-021-04204-x 10.1016/S2352-4642(19)30116-6 10.1016/j.amjsurg.2011.04.008 10.1002/cncr.26578 10.1200/JCO.2006.08.8310 10.1016/j.jaad.2012.12.953 10.1016/S1470-2045(13)70608-9 10.1111/jdv.14299 10.1097/EDE.0000000000000963 10.1200/JCO.2005.02.899 10.1111/j.1365-4632.2008.03653.x 10.1186/s12885-020-07319-w 10.1289/ehp.1408548 10.2340/00015555-1078 10.1093/ije/dyn132 10.2105/AJPH.79.2.152 10.1097/CEJ.0b013e32833b492f 10.2471/BLT.07.043497 10.1097/CEJ.0b013e32832caab5 10.1016/j.jaad.2014.09.049 10.1111/jdv.12905 10.1111/pcmr.12584 10.1016/j.mehy.2012.01.028
European Journal of Pediatrics; Cristina F, Simona M et. al.
Jul 19th, 2021 - It is not known if children and adolescents with atypical Spitz tumour and cutaneous melanoma differ in terms of etiological factors. The aim of this study was to explain differences in individual and environmental factors between cutaneous melano...
https://doi.org/10.1007/s00262-021-03007-1 10.1038/nrc.2016.36 10.1016/j.coi.2011.12.009 10.1016/j.humpath.2017.06.012 10.3389/fonc.2017.00233 10.1016/j.ctrv.2015.11.001 10.1038/s41388-018-0303-3 10.3389/fimmu.2019.01337 10.1016/j.cell.2015.05.044 10.1016/j.celrep.2017.04.031 10.1136/jclinpath-2017-204853 10.1182/blood-2006-10-051482 10.1146/annurev-pathol-012513-104720 10.1038/nrclinonc.2018.29 10.1002/ijc.30077 10.1158/0008-5472.CAN-13-0992 10.1016/j.eururo.2015.11.029 10.1084/jem.20131916 10.1080/2162402X.2015.1108514 10.1016/j.cell.2018.09.006 10.1093/nar/gkv1471 10.1111/pcmr.12774 10.1373/clinchem.2008.112797 10.1158/0008-5472.can-03-1339 10.1186/1471-2407-10-386 10.1038/emboj.2012.231;10.1038/emboj.2012.231 10.1038/sj.onc.1208513 10.1016/j.phrs.2020.104727 10.1002/ijc.30429 10.1073/pnas.1607836113 10.1158/2326-6066.CIR-17-0537 10.1038/nature22396
Cancer Immunology, Immunotherapy : CII; van Duijn A, Willemsen KJ et. al.
Jul 17th, 2021 - Cancer cells are able to escape immune surveillance by upregulating programmed death ligand 1 (PD-L1). A key regulator of PD-L1 expression is transcriptional stimulation by the IFNγ/JAK/STAT pathway. Recent studies suggest that hypoxia can induce ...
Guidelines 7 results
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.
Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.
Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.
Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...
https://doi.org/10.6004/jnccn.2018.0042
Journal of the National Comprehensive Cancer Network : JN... Barker CA, Salama AK
May 23rd, 2018 - The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCC...
https://doi.org/10.1093/annonc/mdv297
Annals of Oncology : Official Journal of the European Soc... Dummer R, Hauschild A et. al.
Sep 1st, 2015 - Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2015|Dummer R,Hauschild A,Lindenblatt N,Pentheroudakis G,Keilholz U,|diagnosis,pathology,therapy,
Drugs 1 results see all →
Clinicaltrials.gov 48 results
https://clinicaltrials.gov/ct2/show/NCT02535078
Apr 21st, 2020 - This study is a Phase Ib/II, multi-center, open-label study of IMCgp100 as a single agent and in combination with durvalumab (MEDI4736) and/or tremelimumab in metastatic cutaneous melanoma. The purpose of this study is to characterize the safety, ...
https://clinicaltrials.gov/ct2/show/NCT00539591
Apr 10th, 2020 - This study is for children with malignant melanoma and high risk features (at high risk of melanoma returning or spreading to other parts of the body) or who have recurrent disease. The study has two treatment groups based on the stage of the dise...
https://clinicaltrials.gov/ct2/show/NCT03655756
Feb 27th, 2020 - Six male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with unresectable stage III or stage IV cutaneous melanoma with accessible lesions, will be eligible for enrollment and treatment with IFx-Hu...
https://clinicaltrials.gov/ct2/show/NCT03276832
Jan 30th, 2020 - PRIMARY OBJECTIVES: I. To gain preliminary data of the anti-tumor activity and safety profile of the combination of imiquimod and pembrolizumab in patients with unresectable cutaneous melanoma. SECONDARY OBJECTIVES: I. To compare and contrast (in ...
https://clinicaltrials.gov/ct2/show/NCT02581930
Jan 9th, 2020 - PRIMARY OBJECTIVES: I. Estimate rate of objective response (OR: complete response [CR] + partial response [PR]) to ibrutinib administered as single agent in patients with immune checkpoint inhibitor-refractory, or immune checkpoint inhibitor ineli...
News 98 results
https://www.medscape.com/viewarticle/955112
Jul 20th, 2021 - Declining trends in melanoma death rates accelerated from 2014 to 2018 in the United States, even as incidence rates increased for both males and females, according to an annual report by several national organizations. "Death rates for cutaneous ...
https://www.medscape.com/viewarticle/943086
Dec 23rd, 2020 - NEW YORK (Reuters Health) - The association between ultraviolet (UV) exposure and melanoma is "weak" for skin of color, according to a new systematic review. "I was not surprised to find little to no evidence supporting the association between UV ...
https://www.medscape.com/viewarticle/940924
Nov 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Initial evidence suggests that the deliberate delays in melanoma care that occurred during the COVID-19 shelter-in-place lockdown last spring had ...
https://www.medscape.com/viewarticle/940003
Oct 30th, 2020 - NEW YORK (Reuters Health) - Compared with wide local excision (WLE), Mohs micrographic surgery (MMS) does not appear to increase overall survival in patients with trunk or extremity melanomas, according to a retrospective study. "In contrast to ou...
https://www.medscape.com/viewarticle/938007
Sep 25th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...
